Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Potential for micro-RNA based cancer treatments

Prof Carlo Croce – Ohio State University, Columbus, USA
Potential for micro-RNA based cancer treatments ( Prof Carlo Croce – Ohio State University, Columbus, USA )
18 Jul 2012

Bevacizumab benefits beyond progression in TML study subgroups

Dr Thierry André – Hôpital Saint Antoine, Paris, France
Bevacizumab benefits beyond progression in TML study subgroups ( Dr Thierry André – Hôpital Saint Antoine, Paris, France )
17 Jul 2012

Translational and tailored, but can we afford it?

Prof Gordon McVie - European Institute of Oncology and ecancer
Translational and tailored, but can we afford it? ( Prof Gordon McVie - European Institute of Oncology and ecancer )
17 Jul 2012

Translational and tailored, but can we afford it?

Prof Ulrik Ringborg - Karolinska Institute, Stockholm, Sweden
Translational and tailored, but can we afford it? ( Prof Ulrik Ringborg - Karolinska Institute, Stockholm, Sweden )
17 Jul 2012

Cost efficiency of targeted therapy

Dr Maria Grazia Daidone - Foundazione IRCCS Istituto Nazionale dei Tumori, Italy
Cost efficiency of targeted therapy ( Dr Maria Grazia Daidone - Foundazione IRCCS Istituto Nazionale dei Tumori, Italy )
17 Jul 2012

Translating cancer research to personalised treatment: Can it work?

Prof Joan Seoane – Vall d’Hebron Institute of Oncology, Spain
Translating cancer research to personalised treatment: Can it work? ( Prof Joan Seoane – Vall d’Hebron Institute of Oncology, Spain )
17 Jul 2012

The immuno side of melanoma

Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
The immuno side of melanoma ( Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
16 Jul 2012

Constructing successful biomarker clinical trials

Dr Lisa McShane – National Cancer Institute, Bethesda, USA
Constructing successful biomarker clinical trials ( Dr Lisa McShane – National Cancer Institute, Bethesda, USA )
16 Jul 2012

Highlights of the 22nd EACR meeting and tackling glioblastoma

Dr Joan Seoane – Vall d’Hebron Institute of Oncology, Spain
Highlights of the 22nd EACR meeting and tackling glioblastoma ( Dr Joan Seoane – Vall d’Hebron Institute of Oncology, Spain )
16 Jul 2012

The changing field of drug development

Dr Jonathan Yingling – Oncology Drug Discovery, Eli Lilly
The changing field of drug development ( Dr Jonathan Yingling – Oncology Drug Discovery, Eli Lilly )
16 Jul 2012

Epigenetics of cancer and changes in DNA modification in tumours

Prof Manel Esteller – University of Barcelona, Catalonia, Spain
Epigenetics of cancer and changes in DNA modification in tumours  ( Prof Manel Esteller – University of Barcelona, Catalonia, Spain   )
16 Jul 2012

Adjuvant cetuximab disappoints again in mCRC

Prof Michel Ducreux – Institut Gustave Roussy, Villejuif, France
Adjuvant cetuximab disappoints again in mCRC ( Prof Michel Ducreux – Institut Gustave Roussy, Villejuif, France )
16 Jul 2012